

POWERED BY COR2ED

PRACTICAL CONSIDERATIONS WHEN SEQUENCING TREATMENTS FOR mCRPC PATIENTS IN CLINICAL PRACTICE

Joanne Chien, MSN, RN, GNP-BC Stanford Health Care, Palo Alto, CA, USA

AUGUST 2021

DISCLAIMER AND DISCLOSURE



Please note: The views expressed within this presentation are the personal opinions of the author. They do not necessarily represent the views of the author's academic institution or the rest of the GU NURSES CONNECT group.

This content is supported by an Independent Educational Grant from Bayer.

Joanne Chien does not have any relevant financial relationships to disclose.

INTRODUCTION




- Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have increased dramatically over recent years
- Prior treatments during metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) impact future treatment decisions
 - mCRPC patients may have already received treatment with an androgen-receptor pathway inhibitor (ARPI)
- Sequencing is evolving: numerous studies ongoing to develop new therapies, optimise sequencing and/or combination therapies
- Cross-resistance can occur with ARPIs so it is preferable to select subsequent therapies with a different mechanism of action
- Real-world findings provide valuable information, including data in patients with comorbidities

ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer

1. Lowrance W, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO guideline. Available from https://www.auanet.org/guidelines/advanced-prostate-cancer. Accessed Jul 30, 4 2021; 2. NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer, version 2.2021. Accessed Jul 30, 2021

APPROVED TREATMENTS FOR mCSPC AND nmCRPC





*Level-1 evidence, no SNDA filed


FDA, Food & Drug Administration; mCSPC, metastatic castration-sensitive prostate cancer; nmCRPC, non-metastatic castration-resistant prostate cancer; SNDA, supplementary new drug application

www.fda.gov

APPROVED TREATMENTS FOR mCRPC



• Treatment choice for mCRPC is dependent on prior treatments received during mCSPC (doce, abi, enza, apa) or nmCRPC (apa, enza, daro)



*Progressed following androgen-axis targeted treatment and taxane-based chemotherapy; **Progressed following treatment with enzalutamide or abiraterone abi, abiraterone; apa, apalutamide; BRCA, breast cancer; daro, darolutamide; dMMR, deficient DNA mismatch repair; doce, docetaxel; enza, enzalutamide; FDA, Food & Drug Administration; HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; MSI-H, microsatellite instability-high. www.fda.gov



National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2021 Prostate Cancer NCCN Guidelines Index Table of Contents Discussion

SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMAzz,ccc,ddd,eee

No prior docetaxel/no prior novel hormone therapy ^{fff} • Preferred regimens • Abiraterone ^{t,ggg} (category 1 ^{hhh}) • Docetaxel ^{aaa,iii} (category 1) • Enzalutamide ^t (category 1) • Useful in certain circumstances • Sipuleucel-T ^{aaa,jjj} (category 1) • Radium-223 ^{kkk} for symptomatic bone metastases (category 1) • Other recommended regimens • Other secondary hormone therapy ^t	Prior novel hormone therapy/No prior docetaxel Preferred regimens Docetaxel (category 1) ^{aaa} Sipuleucel-T ^{aaa,JJJ} Useful in certain circumstances Olaparib for HRRm (category 1) ^{mmm} Cabazitaxel/carboplatin ^{aaa,nnn} Pembrolizumab for MSI-H or dMMR ^{aaa} Radium-223 ^{kkk} for symptomatic bone metastases (category 1) Rucaparib for BRCAm ^{ooo} Other recommended regimens Abiraterone ^{t,ggg} Abiraterone + dexamethasone ^{ggg,ppp} Enzalutamide ^t Other secondary hormone therapy ^t
 Prior docetaxel/no prior novel hormone therapy^{fff} Preferred regimens Abiraterone^{t, 999} (category 1) Cabazitaxel^{aaa} Enzalutamide^t (category 1) Useful in certain circumstances Mitoxantrone for palliation in symptomatic patients who cannot tolerate other therapies^{aaa} Cabazitaxel/carboplatin^{aaa,nnn} Pembrolizumab for MSI-H or dMMR^{aaa} Radium-223^{kkk} for symptomatic bone metastases (category 1) Other recommended regimens Sipuleucel-T^{aaa,jjj} Other secondary hormone therapy^t 	 Prior docetaxel and prior novel hormone therapy^{fff,III} (All systemic therapies are category 2B if visceral metastases are present) Preferred regimens Cabazitaxel^{aaa} (category 1^{hhh}) Docetaxel rechallenge^{aaa,eee} Useful in certain circumstances Olaparib for HRRm (category 1)^{hhh,mmm} Cabazitaxel/carboplatin^{aaa,nnn} Pembrolizumab for MSI-H or dMMR^{aaa} Mitoxantrone for palliation in symptomatic patients who cannot tolerate other therapies^{aaa} Radium-223^{kkk} for symptomatic bone metastases (category 1^{hhh}) Rucaparib for BRCAm^{ooo} Other recommended regimens Abiraterone^{t,ggg} Enzalutamide^t Other secondary hormone therapy^t

BRCAm, breast cancer mutated; dMMR, deficient DNA mismatch repair; HRRm, homologous recombination repair mutated; MSI-H, microsatellite instability-high NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer, version 2.2021. Accessed Jul 30, 2021

TREATMENT PATTERNS IN PATIENTS WITH mCRPC IN A REAL-WORLD CLINICAL PRACTICE SETTING IN THE UNITED STATES


Duration of mCRPC treatment by line of therapy for 1L, 2L and 3L therapies

	Treatment duration, months ^a						
	1L		2L		3L		
Treatment	N	Median (min-max)	N	Median (min-max)	N	Median (min-max)	
Docetaxel	293	4.6 (0.03-28.9)	137	3.8 (0.03-37.2)	101	4.1 (0.03-20.8)	
Abiraterone	742	5.4 (0.03-47.5)	193	4.8 (0.03-53.4)	59	4.2 (0.3-17.5)	
Enzalutamide	552	5.8 (0.03-48.6)	326	5.4 (0.03-36.5)	68	4.0 (0.03-27.2)	
Other combination	107	4.7 (0.27-28.6)	112	4.3 (0.03-24.0)	51	4.9 (0.03-28.4)	
Sipuleucel-T	140	3.5 (0.03-51.4)	16	2.5 (0.03-6.8)	14	2.8 (0.03-13.2)	
Cabazitaxel	22	2.2 (0.03-6.3)	61	2.6 (0.03-26.3)	46	3.1 (0.03-24.5)	
Radium overall	94	6.0 (0.03-34.4)	85	5.0 (0.03-22.7)	56	4.4 (0.03-13.1)	
Radium-223	47	4.7 (0.03-16.1)	32	4.9 (0.03-13.3)	33	5.1 (0.03-11.0)	
Radium combination	47	7.3 (0.7-34.4)	53	5.2 (0.4-22.7)	23	4.1 (0.8-13.1)	
Other	30	1.9 (0.03-18.4)	39	1.9 (0.03-22.9)	19	1.7 (0.4-12.9)	

^aIn cases in which patients were treated with combination therapy, the duration of therapy was defined as the period between the first and last administration of any agent(s) in the combination

Patients with mCRPC receiving various lifeprolonging therapies in the 1L, 2L and 3L settings

POWERED BY COR2ED




Monotherapy Combination therapy with radium-223 Other Combination therapy

1L, first line; 2L, second line; 3L, third line; mCRPC, metastatic castration-resistant prostate cancer George D, et al. Clinical Genitourinary Cancer. 2020;18:284-94

TREATMENT PATTERNS IN PATIENTS WITH mCRPC IN A REAL-WORLD CLINICAL PRACTICE SETTING IN THE UNITED STATES



THE PROPORTION OF PATIENTS WITH mCRPC RECEIVING LIFE-PROLONGING ANTICANCER THERAPIES IN THE 1L, 2L AND 3L SETTINGS



A total of 23%, 28% and 29% of patients did not receive a subsequent line of therapy after 1L, 2L and 3L therapy, respectively. In this Sankey diagram, a node to the right illustrates patients with mCRPC (grey) transitioning to a subsequent line of therapy (green) or death without receiving a subsequent line (blue).


- The median OS was longer in patients who received life-prolonging therapies (23.7 months; 95% CI: 22.3-25.1 months) than in those who did not (10.1 months; 95% CI: 9.1-11.5 months)
- Underutilisation of life-prolonging treatment
- Most common therapies per line: abiraterone/prednisone (1L), enzalutamide (2L), docetaxel (3L)
- Back-to-back use of abiraterone/prednisone and enzalutamide was common despite known cross-resistance
- The results suggested an underutilisation of radium-223 and BHAs

1L, first line; 2L, second line; 3L, third line; BHAs, bone health agents; Cl, confidence interval; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival George D, et al. Clinical Genitourinary Cancer. 2020;18:284-94

CARD STUDY DESIGN



- Phase 4 trial of cabazitaxel vs. abiraterone or enzalutamide in previously treated mCRPC patients
 - Multicenter, randomised, open-label study
 - Enrolment: Nov 2015 Nov 2018
 - Median follow-up: 9.2 months



- Time to progression on prior alternative ARTA (0–6 vs >6–12 months)
- Timing of ARTA (before vs after docetaxel)


1. de Wit R, et al. Ann Oncol. 2019;30(suppl_5):v851-v934; 2. de Wit R, et al. N Engl J Med. 2019;381:2506-18.

ARTA, androgen receptor-targeted agents; ECOG PS, eastern cooperative oncology group performance status; G-CSF, granulocyte colony stimulating factor; HRQoL, health-related quality of life; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; Q3W, every three weeks; QD, once daily; (r)PFS, (radiographic) progression free survival; PSA, prostate-specific antigen

CARD STUDY: PRIMARY ENDPOINT




RADIOGRAPHIC PROGRESSION-FREE SURVIVAL



CARD STUDY: SECONDARY ENDPOINTS





OVERALL SURVIVAL

- Chemotherapy with cabazitaxel was superior to the alternate NHA:
 - Improved OS, PFS, PSA response, tumour response, pain response, time to SSE
- No new safety signals were observed
- Improved QOL favouring cabazitaxel
- Cabazitaxel should be offered prior to 2nd NHA

CI, confidence interval; NHA, novel hormonal agents; OS, overall survival; PFS, progression-free survival; PSA, prostate-specific antigen, SSE, symptomatic skeletal event; QOL, quality of life

1. de Wit, R et al. N Engl J Med. 2019;381:2506-18; 2. Fizazi K, et al. Lancet Oncol. 2020:21:1513-25

PROGRESSION-FREE SURVIVAL

REAL-WORLD EVIDENCE FOR PATIENTS WITH mCRPC TREATED WITH CABAZITAXEL



13


COMPARISON WITH THE RANDOMISED CLINICAL STUDY CARD


	CARD-like cohort cabazitaxel (N=452)	CARD study cabazitaxel (N=129)
Treatment duration Median duration of treatment exposure, weeks (range) Treatment with first ARTA, weeks (range) ≤12 months >12 months Median number of cycles, n (range)	12.9 (1.0-117.4) 21.6 (1.0-117.4), n=136 25.9 (1.0-108.6), n=297 6 (1-15) ^b	22.0 (3.0-88.0) 23.9 (3.0-87.9) 21.6 (6.0-51.7) 7.0 (1.0-29.0)
Treatment reduction Patients with ≥1 cycle administered at reduced dose, n (%)	250 (55.3)	27 (21.4)
Treatment discontinuation Patients who discontinued treatment, n (%)	452 (100)	120 (95.2)
Reasons for discontinuation Disease progression Adverse event Investigator decision Patient request Other reason To improve quality of life Not reported	293 (64.8) - - 39 (8.6) 29 (8.6) 24 (5.3) 57 (12.6)	55 (43.7) 25 (19.8) 21 (16.7) 12 (9.5) 7 (5.6) - 0


- More patients received both abi and enza before cabazitaxel despite evidence of crossresistance
- More patients received lower dose; however, duration of treatment was comparable to the CARD study despite poorer ECOG and more aggressive disease features
- Treatment with ARTA beyond PSA progression is common
- Reflective of the CARD study population

Abi, abiraterone; ARTA, androgen receptor-targeted agent; ECOG, Eastern Cooperative Oncology Group; enza, enzalutamide; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen de Wit R, et al. Ann of Oncol. 2020:31(suppl 4):S518 (ESMO 2020 poster)

CONCURRENT OR LAYERED TREATMENT WITH RADIUM-223 GUnurses AND ENZALUTAMIDE OR ABIRATERONE/PREDNISONE







With concomitant BHAs

SUMMARY OF OVERALL SURVIVAL

	Radium-223 + abiraterone/prednisone (N=136)		Radiun enzalu (N=:	All patients (N=625)	
	Concurrent (n=39)	Layered (n=97)	Concurrent (n=44)	Layered (n=123)	
Median follow-up time, months (range)	13 (0-40)	10 (0-42)	12 (1-40)	10 (0-32)	9 (0-46)
Median OS from mCRPC diagnosis, months (95% CI)	28.3 (18.4-NR)	34.5 (25.9–50.9)	28.1 (16.7-NR)	26.9 (25.0-34.4)	28.1 (25.7-30.4)
Median OS from radium-223 initiation, months (95% CI)	22.1 (14.7-NR)	19.3 (11.3-27.5)	19.1 (12.3-NR)	15.2 (11.6-16.3)	15.2 (13.2-16.3)


- Combination of radium-223 with either abiraterone/prednisone or enzalutamide was common in the US clinical setting
 - Layered approach (≥30 days) was more common than concurrent (within 30 days)
 - Lower incidence of pathological fracture in patients receiving BHAs
 - BHAs were underutilized


BHA, bone health agent; CI, confidence interval; mCRPC, metastatic castration-resistant prostate cancer; NR, not reached; OS, overall survival; SSE, symptomatic skeletal event

Shore N, et al. Prostate Cancer and Prostatic Dis. 2020;23:680-8


PHENIX REAL-WORLD STUDY: SEQUENTIAL NAH OR RA-223 AFTER PROGRESSION ON 1L NAH







- Patients on 2L Ra-223 had similar rates of subsequent life-prolonging therapies as patients on 2L NAH (49% vs 39%)
- The rate of SSEs after 2L start was similar in both cohorts




2L, second line; BHA, bone health agents; CI, confidence interval; NAH, novel antihormone; Ra-223, radium-223; OS, overall survival; SSE, symptomatic skeletal event Sartor O, et al. J Clin Oncol. 2021;39(suppl_6):abstract 48 (ASCO GU 2021 poster)

Ra-223 EARLY VS LATE IN THE TREATMENT SEQUENCE REAL-WORLD DATA



16


- Patients who received Ra-223 in second-line versus third-line or later had better outcomes
- Patients who received Ra-223 early received less chemotherapy, but had better survival
- EFS was better in the early vs late Ra-223 cohort (HR 0.71, 95% CI 0.58-0.86)



ADT, androgen deprivation therapy; CCI, Charlson Comorbidity Index; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; LPT, life-prolonging therapy; mCRPC, metastatic castration-resistant prostate cancer; Ra-223, radium-223; TNM, tumour, node, metastasis Mbuagbaw L, et al. J Clin Oncol. 2021;39(suppl 6):abstract 136 (ASCO GU 2021 poster presentation)

VISION TRIAL: LUTETIUM-177-PSMA-617 FOR mCRPC





 Androgen receptor pathway inhibitors in SOC (yes or no)

central review


CT, computerised tomography; ECOG, Eastern Cooperative Oncology Group; Ga, gallium; GBq, gigabecquerel; LDH, lactate dehydrogenase; Lu-177, lutetium-177; mCi, millicurie; mCRPC, metastatic castration-resistant prostate cancer; MRI, magnetic resonance imaging PET, positron emission tomography; PSMA, prostate-specific membrane antigen; SOC, standard of care Sartor O, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107322 (ASCO 2021 oral presentation)

VISION TRIAL: LUTETIUM-177-PSMA-617 FOR mCRPC



ALTERNATE PRIMARY ENDPOINTS

Imaging-based progression-free survival




ARI, androgen receptor inhibitor; CI, confidence interval; Lu-177, lutetium-177; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; PFS, progression-free survival; PSMA, prostate-specific membrane antigen; SOC, standard of care; QOL, quality of life Sartor O, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107322

VISION TRIAL: LUTETIUM-177-PSMA-617 FOR mCRPC SECONDARY ENDPOINT



• Lu-177 prolonged time to symptomatic skeletal events compared with SOC

Time to first symptomatic skeletal event



CI, confidence interval; Lu-177, lutetium-177; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; SOC, standard of care Sartor O, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107322

SUMMARY



- Practical considerations when sequencing mCRPC treatments:
 - Consider prior therapies and sandwich therapies of different mechanism of actions or consider combination therapy
 - Consider sites of metastases (visceral vs. bone disease)
 - Is the patient symptomatic vs. asymptomatic?
 - Presence vs. absence of genomic/germline mutations indicates suitability for PARPi, immunotherapy, clinical trials
 - Patient preferences: oral vs. IV; side effects of therapies; goals of care; quality of life
 - Supportive care (BHA for mCRPC, managing side effects)
- Goal is to choose the right therapy at the right time, deliver all effective life-prolonging therapies and balance quality of life

REACH GU NURSES CONNECT VIA TWITTER, LINKEDIN, VIMEO & EMAIL OR VISIT THE GROUP'S WEBSITE https://gunursesconnect.info/



Follow us on Twitter <u>@gunursesconnect</u> Follow the GUNURSESCOR2ED Group on LinkedIn Watch us on the Vimeo Channel GUNURSES CONNECT Email sam.brightwell @cor2ed.com



POWERED BY COR2ED

GU Nurses CONNECT Bodenackerstrasse 17 4103 Bottmingen SWITZERLAND

Dr. Froukje Sosef MD



 \bowtie

+31 6 2324 3636

froukje.sosef@cor2ed.com

Dr. Antoine Lacombe Pharm D, MBA



- +41 79 529 42 79
- antoine.lacombe@cor2ed.com



Connect on LinkedIn @GU Nurses CONNECT







Visit us at gunursesconnect.info



Follow us on Twitter @gunursesconnect

NNECT

Peter

Froukje

Ewen

Veronica

Elaine